priceless, OH CHUCK
from one bunch of clowns t o the current BOD ("experienced financial and deal-making professionals)
From the new home of our $8M IP, say $2B jsut over the near term horizon
"We believe that PS targeting possesses significant promise in the treatment of cancer and look forward to highlighting the therapeutic potential of the approach through innovative clinical trials through this agreement with Avid," said Oncologie CEO Laura Benjamin.
Bavituximab has also been studied in pancreatic cancer, breast cancer, glioblastoma and chronic hepatitis C infection, and clinical trials for bavituximab in breast cancer and prostate cancer have been terminated or withdrawn.
News 
Market Data 
Discover 
